Welcome to our dedicated page for Recursion Pharmaceuticals SEC filings (Ticker: RXRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Recursion Pharmaceuticals, Inc. filings document the regulatory record for a clinical-stage TechBio company advancing investigational medicines through an AI-native discovery and development platform. Its 8-K reports disclose operating results, financial condition, Regulation FD presentations, clinical and pipeline updates, partner milestones and material corporate events.
Proxy materials cover annual-meeting matters, director elections, executive compensation and governance practices. Other filings include leadership-transition disclosures, shelf-registration and prospectus-supplement records for Class A common stock, and capital-structure disclosures tied to shares issued under the Tempus master agreement.
Issuer filed a Rule 144 notice reporting restricted Class A shares sold under Rule 144. The filing lists sales by Blake C. Borgeson of 170,000 shares on 03/03/2026 for $588,200 and 30,000 shares on 04/07/2026 for $93,000. It also shows an earlier 30,000-share issuance dated 09/19/2017 labeled "Founders Shares" and a broker record for 30,000 shares at Fidelity Brokerage Services.
Recursion Pharmaceuticals, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 17, 2026 at 12:00 P.M. Mountain Time. The agenda includes electing two Class II directors, an advisory “say‑on‑pay” vote on executive compensation, and ratifying PricewaterhouseCoopers LLP as independent auditor for 2026.
The company highlights its AI‑native TechBio business model, dual‑class share structure with Class A at one vote and Class B at ten votes per share, and a 10‑member, largely independent and diverse board. It details virtual‑only participation, broker voting rules, and committee responsibilities for audit, compensation, governance, R&D, technology, social responsibility, and strategic transactions.
Recursion outlines a pay‑for‑performance philosophy, with 2025 annual incentives paid at 80% of target and a heavy emphasis on stock options and RSUs. The proxy also describes a CEO transition effective January 1, 2026 from co‑founder Christopher Gibson to Najat Khan and raises outside director retainers and equity awards starting April 1, 2026.
Recursion Pharmaceuticals announced a planned board transition involving its founder and current Chair, Chris Gibson, Ph.D. On April 28, 2026 he informed the company that he will not stand for re-election as a Class II director at the 2026 Annual Meeting of Stockholders.
The filing states his decision is not due to any disagreement with the company on operations, policies, or practices. Dr. Gibson will continue serving as Chair of the Board and on its committees through the end of his current term and will remain involved as a strategic advisor thereafter, supporting leadership continuity.
Recursion Pharmaceuticals director Christopher Gibson reported an exercise-and-sell style transaction involving 40,000 shares of Class A Common Stock. He converted 40,000 shares of Class B Common Stock into 40,000 Class A shares and then sold 40,000 Class A shares in an open-market transaction at $3.61 per share.
According to a footnote, this activity was carried out under a pre-arranged Rule 10b5-1 trading plan adopted by Gibson on May 12, 2025. After these moves, he holds 906,556 Class A shares directly, along with 4,403,334 Class B shares directly and additional Class B shares held indirectly through family entities.
BlackRock, Inc. filed Amendment No. 4 to a Schedule 13G/A reporting beneficial ownership of 37,821,797 Class A shares of Recursion Pharmaceuticals. The filing states this equals 7.2% of the Class A stock and shows 37,178,542 shares for which BlackRock has sole voting power. The signature is dated 04/24/2026 and the cover date is 03/31/2026.
Christopher C. Gibson reported multiple Class A share sales under Form 144. The filing lists four transactions: 40,000 shares on 02/04/2026 (proceeds $164,800), 40,000 shares on 02/19/2026 (proceeds $138,400), 40,000 shares on 03/23/2026 (proceeds $130,000), and 40,000 shares on 04/07/2026 (proceeds $124,000).
The transactions are shown as sales of Founders Shares and identify Fidelity Brokerage Services LLC as a broker. Timing and cumulative holdings after these sales are not stated in the excerpt.
Recursion Pharmaceuticals CFO Ben R. Taylor reported a tax-related share disposition. On April 6, 2026, 48,028 shares of Class A Common Stock at $3.11 per share were withheld by the company to cover tax obligations from net settlement of restricted stock units. After this withholding, Taylor directly owns 1,132,290 shares of the company’s Class A Common Stock.
Recursion Pharmaceuticals director Christopher Gibson converted and sold shares of the company’s stock. On April 7, he converted 40,000 shares of Class B Common Stock into 40,000 shares of Class A Common Stock and then sold 40,000 Class A shares at $3.10 per share in an open-market transaction.
The trades were made pursuant to a Rule 10b5-1 trading plan adopted on May 12, 2025. Following these transactions, he directly holds 906,556 shares of Class A Common Stock and 4,443,334 shares of Class B Common Stock, while various family entities no longer show Class B holdings in this filing.
Recursion Pharmaceuticals director Blake Borgeson reported an open-market sale of Class A Common Stock. On this transaction date, he sold 30,000 shares at a price of $3.10 per share. After the sale, he directly held 6,229,863 shares of Class A Common Stock.
The sale was executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted by Borgeson on August 31, 2025, indicating the trade was scheduled in advance rather than timed discretionarily.